Omeros Announces Dosing Of First Patient In Second OMS824 Phase 2 Trial

(RTTNews) - Omeros Corp. (OMER) announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 inhibitor being developed for the treatment of schizophrenia, Huntington's disease and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic Huntington's disease.

Omeros previously reported results from its successful Phase 2 trial of OMS824 in patients with schizophrenia. The second Phase 2 trial will enroll approximately 120 patients with Huntington's disease who will be randomized to receive placebo or one of three doses of OMS824. The company expects interim results in the second half of the current year with final data projected to be available in 2015.